<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>pharmaceuticals on FinanClub</title>
    <link>https://finan.club/tags/pharmaceuticals/</link>
    <description>Recent content in pharmaceuticals on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 16 Jan 2024 09:05:48 +0000</lastBuildDate><atom:link href="https://finan.club/tags/pharmaceuticals/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PFE</title>
      <link>https://finan.club/us/pfe/</link>
      <pubDate>Tue, 16 Jan 2024 09:05:48 +0000</pubDate>
      
      <guid>https://finan.club/us/pfe/</guid>
      <description>score:53
Chances: Pfizer&amp;rsquo;s work in developing new drugs and breaking into the obesity market shows potential for future growth and innovation. Pharmaceutical executives are plotting to break into the lucrative obesity market, indicating a potential opportunity for Pfizer to expand its product portfolio.</description>
    </item>
    
    <item>
      <title>OGN</title>
      <link>https://finan.club/us/ogn/</link>
      <pubDate>Wed, 20 Dec 2023 09:03:44 +0000</pubDate>
      
      <guid>https://finan.club/us/ogn/</guid>
      <description>score:21
Chances: Organon&amp;rsquo;s partnership with Sempre Health to improve medication adherence shows a proactive approach to patient care and may lead to increased sales. The company&amp;rsquo;s exclusive distribution of Emgality and RAYVOW in Europe presents a significant opportunity for revenue growth in the region.</description>
    </item>
    
    <item>
      <title>AZN</title>
      <link>https://finan.club/us/azn/</link>
      <pubDate>Tue, 19 Dec 2023 09:06:54 +0000</pubDate>
      
      <guid>https://finan.club/us/azn/</guid>
      <description>score:-135
Chances: AstraZeneca (AZN) closed at $65.95, indicating a +1.77% shift from the previous trading day. AstraZeneca (AZN) announces that it is buying vaccine company, Icosavax. The additional supply of RSV shot for infants by AstraZeneca and Sanofi indicates a positive outlook for meeting winter demand.</description>
    </item>
    
  </channel>
</rss>
